CAS 1189685-70-8

Vardenafil

Description:

Vardenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor primarily used for the treatment of erectile dysfunction. It works by enhancing the effects of nitric oxide, leading to increased blood flow to the penis during sexual stimulation. Vardenafil is characterized by its chemical formula, which includes a complex structure featuring a piperazine ring and a pyrimidine moiety. The substance is typically administered in oral form and is known for its rapid onset of action, often within 30 minutes, with effects lasting for several hours. Vardenafil is metabolized primarily in the liver, and its pharmacokinetics can be influenced by factors such as food intake and individual metabolic rates. Common side effects may include headaches, flushing, and nasal congestion, while serious adverse effects are rare but can include priapism and cardiovascular events. As with any medication, it is essential for users to consult healthcare professionals to ensure safe and appropriate use, particularly in individuals with pre-existing health conditions or those taking other medications.

Vardenafil-d5

CAS: 1189685-70-8

Formula: C₂₃H₂₇D₅N₆O₄S

Color and Shape: White To Off-White Solid

Molecular weight: 493.64

Ref: 4Z-V-053

Vardenafil-d5

Controlled Product

CAS: 1189685-70-8

Applications Vardenafil-d5 is a labelled selective phosphodiesterase type 5 (PDE5) inhibitor.
References Bischoff, E., et al.: J. Urol., 165, 1316 (2001), Kim, N.N., et al.: Life Sci., 69, 2249 (2001), Kendirci, M., et al.: Expert Opin. Pharmacother., 5, 923 (2004),

Formula: C₂₃₂H₅H₂₇N₆O₄S

Color and Shape: Neat

Molecular weight: 493.63

Ref: TR-V098002

Vardenafil-D5

CAS: 1189685-70-8

Vardenafil-D5 is a deuterated compound of Vardenafil. Vardenafil (T0096) has a CAS number of 224785-90-4. Vardenafil (T0096) (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

Formula: C₂₃H₂₇D₅N₆O₄S

Molecular weight: 493.63

Ref: TM-TMIJ-0114

Vardenafil-[d5] hydrochloride

CAS: 1189685-70-8

Ref: BE-MD-7454

Vardenafil-d5

CAS: 1189685-70-8

Ref: BE-RMCV029022